---
document_datetime: 2023-09-21 17:09:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/fotivda-epar-all-authorised-presentations_en.pdf
document_name: fotivda-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6756382
conversion_datetime: 2025-12-27 13:29:51.103355
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Number                    | (Invented) name   | Strength       | Pharmaceutical Form         | Route of Administration   | Immediate Packaging         | Pack size               |
|-----------------------------------|-------------------|----------------|-----------------------------|---------------------------|-----------------------------|-------------------------|
| EU/1/17/1215/001 EU/1/17/1215/002 | Fotivda Fotivda   | 890 µg 1340 µg | Capsule, hard Capsule, hard | Oral use Oral use         | bottle (HDPE) bottle (HDPE) | 21 capsules 21 capsules |